Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
2(11%)
Results Posted
80%(4 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_3
1
6%
Ph phase_1
1
6%
Ph phase_2
16
89%

Phase Distribution

1

Early Stage

16

Mid Stage

1

Late Stage

Phase Distribution18 total trials
Phase 1Safety & dosage
1(5.6%)
Phase 2Efficacy & side effects
16(88.9%)
Phase 3Large-scale testing
1(5.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

2

trials recruiting

Total Trials

18

all time

Status Distribution
Active(2)
Completed(5)
Terminated(2)
Other(9)

Detailed Status

unknown9
Completed5
Terminated1
Active, not recruiting1
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
18
Active
2
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (5.6%)
Phase 216 (88.9%)
Phase 31 (5.6%)

Trials by Status

completed528%
terminated16%
active_not_recruiting16%
unknown950%
withdrawn16%
recruiting16%

Recent Activity

Clinical Trials (18)

Showing 18 of 18 trials
NCT05027945Phase 2

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Recruiting
NCT01384513Phase 2

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Completed
NCT03674411Phase 2

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Active Not Recruiting
NCT00429143Phase 1

A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative

Completed
NCT01532635Phase 2

A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives

Terminated
NCT05293509Phase 2

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

Withdrawn
NCT05453552Phase 2

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT

Unknown
NCT05449899Phase 2

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT

Unknown
NCT02670252Phase 3

BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT

Completed
NCT02744742Phase 2

G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

Completed
NCT04713956Phase 2

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

Unknown
NCT02671708Phase 2

IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT

Completed
NCT03385096Phase 2

Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT

Unknown
NCT04123392Phase 2

Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT

Unknown
NCT04098653Phase 2

Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT

Unknown
NCT03733327Phase 2

BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT

Unknown
NCT03596892Phase 2

Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT

Unknown
NCT03229616Phase 2

BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT

Unknown

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18